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Hemoglobin is the essential oxygen-carrying molecule in humans and is regulated by cellular
iron and oxygen sensing mechanisms. To search for novel variants associated with hemo-
globin concentration, we performed genome-wide association studies of hemoglobin con-
centration using a combined set of 684,122 individuals from Iceland and the UK. Notably,
we found seven novel variants, six rare coding and one common, at the ACO1 locus asso-
ciating with either decreased or increased hemoglobin concentration. Of these variants,
the missense Cys506Ser and the stop-gained Lys334Ter mutations are specific to eight
and ten generation pedigrees, respectively, and have the two largest effects in the
study (EffectCys506Ser=−1.61 SD, CI95= [−1.98, −1.35]; EffectLys334Ter= 0.63 SD, CI95=
[0.36, 0.91]). We also find Cys506Ser to associate with increased risk of persistent anemia
(OR= 17.1, P= 2 × 10−14). The strong bidirectional effects seen in this study implicate
ACO1, a known iron sensing molecule, as a major homeostatic regulator of hemoglobin
concentration.
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Hemoglobin is a globular protein tetramer in red blood cellsand is the essential oxygen-carrying molecule inhumans1,2. The oxygen-carrying role of hemoglobin is
dependent upon the heme-iron group and red blood cells are
sensitive to iron availability during red blood cell formation.
Hemoglobin synthesis in red blood cell precursors is a process
tightly regulated by several sensors. This includes the highly
conserved cellular iron and oxygen sensing mechanisms that are
linked through the cytokine erythropoietin (EPO), which stimu-
lates precursor cells to differentiate into mature red blood cells3.
Replacement therapy of recombinant human EPO has been used
to treat anemia since the 1990s4. Abnormally low and high
concentration of hemoglobin define anemia and polycythemia,
which are a part of the pathology of several rare Mendelian
disorders5.
A large number of sequence variants have been associated with
variation in hemoglobin concentration through genome-wide
association studies (GWAS)6,7. In particular, a recent study using
a combined cohort of the UK Biobank and interval studies
revealed 140 sequence variants associated with hemoglobin con-
centration8. The majority of the variants reported were common
and only 16 were low frequency (<5%) or rare (<1%). The
majority of the 140 variants associated with hemoglobin con-
centrations are noncoding and it remains unclear which genes
they affect. The largest reported absolute effect on hemoglobin of
one of these variants was 3.1 g/L per allele, corresponding to
0.11 standard deviations (SD), for the intronic variant
rs530159671 in LUC7L8.
We have previously performed GWAS of many phenotypes
using variants identified through whole-genome sequencing of a
large fraction of the Icelandic population (up to 18%). These
studies have uncovered associations of rare and low-frequency
variants with numerous diseases and other traits9–15. Rare var-
iants often represent recent mutations that can be traced to a
single ancestor. Here, through GWAS meta-analysis of 684,122
individuals from Iceland and the UK16, we focus on the rare
missense and loss-of-function variants with large effects on
hemoglobin concentration.
It is unusual to observe variants in the same gene that associate
with a phenotype independently of each other. This is especially
true when the observed variants are rare, coding, and have large
opposing effects on a trait. Therefore, of the loci harboring
common and rare variants associated with hemoglobin con-
centration, we chose to focus on the ACO1 locus to better
understand the effects of sequence variation in this gene on
erythropoiesis in humans. ACO1 is of particular interest as this is
a well characterized gene in cell and animal models, but little has
been reported on the effects of sequence variation on this gene in
humans. We report eight variants associated with hemoglobin
concentration in ACO1, encoding cytosolic aconitase 1 (aka iron-
responsive element binding protein 1 (IRP1)), a protein involved
in cellular iron sensing. These include six rare coding variants,
where four associate with increased and two with decreased
hemoglobin concentration.
Results
In the meta-analysis we combined GWAS results on hemoglobin
concentration from 286,622 Icelanders and 397,500 individuals
from the UK (Supplementary Figs. 1 and 2, Supplementary
Table 1). In Iceland, we tested 37.6 million sequence variants,
identified through whole-genome sequencing of 28,075 Icelanders
and subsequently imputed into 155,250 chip-typed individuals, as
well as 285,664 of their first- and second-degree relatives
(imputation info > 0.8 and MAF > 0.01%)14. Out of a total of
440,914 individuals with genotype information, 286,622 have
hemoglobin measurements available. In the UK, the GWAS was
performed on 40 million markers (imputation info > 0.8), from
the Haplotype Reference Consortium (HRC) reference panel,
imputed into 397,500 chip-typed individuals of European
ancestry from the UK Biobank17 and hemoglobin measurements
were available for all. In total, 43 million markers were tested in
the meta-analysis. Associations were considered significant if the
P value in the combined dataset was below a weighted, Bonferroni
corrected, genome-wide significance threshold based on variant
annotation18 (significance thresholds in “Methods”). Heritability
of hemoglobin concentration in the Icelandic population was
estimated to be 0.20 (95% CI 0.19–0.21) and 0.29 (95% CI
0.29–0.30) using parent–offspring and sibling correlations,
respectively (Supplementary Table 2).
We observe 334 loci harboring sequence variants reaching
genome-wide significance (Supplementary Fig. 3 and Supple-
mentary Data 1). We provide summary statistics for the GWAS
meta-analysis of hemoglobin concentration in Iceland and the
UK for all tested variants (Supplementary Data 1 and “Data
availability” section). In total, 138 variants at 121 loci have pre-
viously been reported to associate with hemoglobin levels in
populations of European descent, for which we provide robust
replication (98%) and demonstrate consistency of effect in the
Icelandic and UK datasets in the current study (Supplementary
Data 2). We observe that genome-wide significant associations of
22 rare coding variants (MAF < 1%) were observed at 13 out of
the 334 loci associated with hemoglobin level (Supplementary
Fig. 3 and Supplementary Data 3). We observe independent rare
coding variants with opposing effects at both the EGLN2 and
ACO1 loci. Rare coding variants in EGLN2 were reported by Astle
et al.8, whereas none have been reported in ACO1.
Five variants in ACO1, encoding cytosolic aconitase 1, also
known as IRP1, associate genome wide significantly with hemo-
globin concentrations, of which three are coding and one com-
mon noncoding variant rs7045087 represents a previously
reported intergenic association8 (Table 1). Subsequently, we tes-
ted the 34 remaining coding variants in ACO1 for association
with hemoglobin concentration and found three additional
associations after accounting for multiple testing (P < 0.05/34=
1.5 × 10−3) (Table 1 and Supplementary Data 4). In total, six of
the eight variants in ACO1 are rare coding (MAF 0.01–0.48%)
that independently associate with hemoglobin concentration with
large effects (effect ranging from −1.61 to 0.63 SD) (Supple-
mentary Figs. 4 and 5, Supplementary Table 3). Of these variants,
three are only present in Iceland, one only in the UK, and two in
both Iceland and the UK (Table 1 and Supplementary Data 5).
We did not observe heterogeneity in the effects of these two
variants between the two countries (Table 1, Supplementary
Data 5). The two common variants at ACO1 are modestly cor-
related (r2= 0.13), but do not explain the effects of each other or
the rare variants (Supplementary Table 3).
We tested the eight hemoglobin associated variants at the
ACO1 locus for association with anemia and polycythemia (five
phenotypes), seven blood cell indices, and five iron biomarkers
(Supplementary Tables 4 and 5), resulting in a total of 136 (eight
times 17) tests and we found 23 associations (P value < 0.05/136
= 3.7 × 10−4) (Tables 2 and 3, Supplementary Data 6–8). All
eight variants associating with hemoglobin also associate with red
blood cell counts (RBC) and hematocrit (HCT) with similar
significance, direction, and magnitude of effect, consistent with
the high correlation between the three phenotypes. Hemoglobin
concentration was used as the primary GWAS phenotype and the
correlated phenotypes for lookup. None of the variants associate
with mean corpuscular volume (MCV) and mean corpuscular
hemoglobin concentration (MCHC) given the number of tests
performed (Supplementary Data 6). Overall this indicates that
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ACO1 sequence variants affect the number of red blood cells but
not their size or the hemoglobin content of individual red blood
cells. In Iceland, we detect an association of one of the variants,
Cys506Ser, with increased serum ferritin levels but none of the
other variants are significant after accounting for multiple testing
(Table 2, Supplementary Table 6 and Supplementary Fig. 6,
Supplementary Data 8).
ACO1 is a cytosolic, RNA-binding protein that regulates the
translation or stability of mRNAs encoding proteins for iron
transport, storage, and use. ACO1 has an alternate function as
cytosolic (c-) aconitase when an iron–sulfur ([4Fe–4S]) cluster is
bound to it. The distribution of ACO1 between these mutually
exclusive activities requires no new protein synthesis; iron excess
or reduction promotes aconitase or RNA-binding activity,
respectively. Assembly and disassembly of the [4Fe–4S] cluster
appears to be an effective mechanism for regulating ACO1
activity, dependent on facile interchange between the two func-
tional conformations19. When iron is low (or NO high, H2O2
high), the iron-responsive element (IRE)-binding activity of
ACO1 increases and it binds IRE in the 5′ and 3′ untranslated
region of mRNAs of many genes involved in iron regulation.
When the concentration of iron increases, an [4Fe–4S] cluster
binds to ACO1 to yield a functional aconitase, which inter-
converts citrate and isocitrate in the cytosol and becomes inactive
as an IRE-binding protein due to a large conformational
change20. Studies with ACO1 null mice21,22 have shown that
ACO1 regulates the hypoxia inducible factor 2alfa (HIF2α) in
similar manner. HIF2α is a transcription factor that is a key
regulator of many genes involved in erythropoiesis including
EPO.
Predicted RNA-binding gain-of-function variants. ACO1 var-
iants that associate with decreased hemoglobin concentration are
predicted to shift the balance of ACO1 function to increased RNA
binding. The ACO1 variant with the largest effect on hemoglobin,
NP_001265281.1:p.Cys506Ser (chr9:32429450[A]), associates
with decreased hemoglobin concentration (Effect=−1.61 SD,
corresponding to 24.6 g/L, P= 2.6 × 10−24, MAFIceland= 0.019%)
(Table 1, Supplementary Data 6). We observed no difference in
effect on hemoglobin concentration between male and female
carriers of Cys506Ser (P= 0.59, nmales= 20, nfemales= 26) (Sup-
plementary Fig. 7a). In Iceland, one in 2600 individuals are het-
erozygous for Cys506Ser (Supplementary Table 7), while it is
absent from other sequenced populations such as the gnomAD
database of 130,000 individuals. We observed 62 heterozygous
carriers of Cys506Ser out of the 155k chip-typed Icelanders, all of
whom belong to a single eight generation pedigree originating
from ancestors born around 1780 in the South-Thingeyjarsysla
county (Fig. 1). Consistent with the large effect on hemoglobin
concentration, we detect an association of Cys506Ser with a high
risk of persistent anemia (all hemoglobin measurements < 118 g/L
for women and <134 g/L for men) (Table 3). Persistent anemia
was observed in 15 (28.3%) of the 53 Cys506Ser carriers with
hemoglobin measurements but only in 1.7% of the general
population (OR= 17.1, P= 2.0 × 10−14). We do not observe
significant association with other diseases in the Icelandic
population, given the number of phenotypes tested (significance
threshold: P < 0.05/413= 1.2 × 10−4) (Supplementary Data 9).
Cys506Ser associates with decreased RBC (Effect=−1.68 SD,
P= 7.5 × 10−25) (Supplementary Data 6), but has no effect on
MCV and MCHC, phenotypically consistent with predisposition
to normocytic anemia (Table 2, Supplementary Data 6). Among
the Cys506Ser carriers, we observe a lower ferritin concentration
(Effect=−0.77 SD, P= 4.1 × 10−6, N= 100,051), but no asso-
ciation with other iron parameters (Table 2, Supplementary
Data 8). Furthermore, no effect was seen on other hematopoietic
lineages (platelets and white blood cells) (Table 2, Supplementary
Data 6).
The Cys506Ser missense variant is at a highly conserved
genomic location among mammalian species (GERP= 5.05, top
20% of the exome and 0.7% of the genome, Supplementary
Table 8) and is one of three cysteine residues (Cys437, Cys503,
and Cys506) involved in direct binding of the [4Fe–4S] cluster to
ACO123–25 (Fig. 2). In vitro and mice studies have shown that
transgenic expression of the Cys506Ser mutation abolishes the
binding of the [4Fe–4S] cluster to ACO1, leading to a
constitutively active RNA-binding state of ACO1, independent
of iron concentration. Consistent with our observations in
humans, the Cys506Ser mice develop anemia26. Furthermore,
the association of Cys506Ser with lower ferritin levels in our data
suggests translational inhibition through the 5′ IRE in ferritin.
Taken together, these data show that Cys506Ser is a gain-of-
function mutation that generates an ACO1 protein with
constitutively active RNA-binding function leading to normocytic
anemia in humans.
Another rare missense variant, NP_001265281.1:p.Thr208Ala,
associates with decreased hemoglobin concentration (rs61753543
[G]) (Effect=−0.18 SD, P= 2.6 × 10−8) (Table 1). The variant
has similar allele frequencies in Iceland and the UK (MAFIceland
= 0.16%, MAFUK= 0.12%, Phet= 0.4) (Supplementary Data 5).
Thr208Ala is at a highly conserved genomic location among
mammalian species (GERP= 5.79, top 4% of the exome and 0.2%
of the genome, Supplementary Table 8) but does not fall within a
known RNA binding or [4Fe–4S] cluster sites (Fig. 2). The
association with decreased hemoglobin concentration suggests
that Thr208Ala increases RNA-binding function of ACO1, either
through increased RNA affinity (binding to IRE) or decreased
binding of [4Fe–4S] cluster to ACO1.
RNA-binding loss-of-function variants. Variants that associate
with increased hemoglobin concentration are predicted to
decrease the RNA-binding function of ACO1. The stop-gained
Table 3 Associations of variants in ACO1 and relevant











OR P OR P
p.Cys506Ser 17.1 2.0E−14 0.01 1.0E−03
rs12985 0.95 5.0E−07 1.06 9.0E−09
p.Arg168Trp 0.71 0.01 1.56 4.0E−09
p.Arg802Cys 0.29 0.12 1.31 0.71
rs7045087 1.02 0.2 0.96 9.0E−05
p.Thr208Ala 1.15 0.3 0.59 4.0E−04
p.Asn549Ile 0.77 0.4 1.74 8.0E−06
p.Lys334Ter 1.4 0.7 3.44 4.0E−04
Persistent anemia is where an individual has all hemoglobin concentration measurements below
defined threshold of anemia based on gender. The polycythemia phenotype was defined as
individuals that were at least once measured to be above the defined threshold of polycythemia
based on gender. Controls for both phenotypes were individuals never reaching the hemoglobin
threshold level for definition of the phenotype based on gender. N cases is the number of
individuals defined to have the phenotype based on hemoglobin measurements (“Methods”). N
controls is the number of individuals that do not fulfill the criteria to be defined with the
phenotype. Effect is shown in odds ratio for the minor allele. Significance levels and effects are
shown for the combined analysis. HGVS is definition the mutation according to the Human
Genome Variation Society nomenclature.
OR odds ratio.
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variant NP_001265281.1:p.Lys334Ter (rs745558996[T]), which is
only detected in the Icelandic dataset, has the largest positive
effect on hemoglobin concentration among ACO1 variants
(Effect= 0.63 SD, corresponding to 9.7 g/L, P= 6.1 × 10−6,
MAFIce= 0.023%) (Table 1, Supplementary Fig. 7b). Through its
hemoglobin increasing effect Lys334Ter associates with increased
risk of polycythemia (OR= 3.3, P= 4.0 × 10−4) (Table 3). No
effects were seen on biomarkers for iron homeostasis (Table 2,
Supplementary Data 8). However, the association of Lys334Ter
with ferritin (Effect= 0.33 SD, P= 0.065) is consistent with the
effect on hemoglobin concentration (Supplementary Table 6 and
Supplementary Fig. 6).
In Iceland, 1 in 2200 individuals are heterozygous for
Lys334Ter, while it is essentially absent from other populations,
only observed in a single Finn in the gnomAD database27. We
observed 67 carriers of Lys334Ter among the 155k chip-typed
Icelanders, all of whom are clustered into a single ten generation
pedigree originating from ancestors born in North Isafjardarsysla
county around year 1710 (Fig. 3). Lys334Ter is located in exon 10
at position 334 out of 889 amino acids in the full-length protein
(Fig. 2)25. Sequencing of RNA isolated from heterozygous carriers
of Lys334Ter (N= 11) and noncarriers (13,152) demonstrated
that transcripts containing Lys334Ter were present in the
heterozygotes and that the amount of total RNA was 17.6% less
in heterozygotes (95% CI −26.7 to −7.5%, P= 0.0011) than in
noncarriers (Supplementary Table 9, Supplementary Fig. 8).
These data are consistent with partial nonsense-mediated decay
of the mutated transcripts. The presence of the mutated transcript
furthermore indicates that a truncated protein is generated. The
truncated protein lacks domains 3 and 4 and part of domain 2
(Fig. 2) and will thus have lost its IRE-RNA-binding ability25.
Consistent with loss of ACO1 RNA-binding function by
Lys334Ter, homozygous knockout mice have increased hemoglo-
bin concentration and polycythemia (Tables 2 and 3)20.
Three additional rare coding variants in ACO1 associate with
increased hemoglobin concentration. First, the missense variant
NP_001265281.1:p.Arg168Trp (rs41305321[T]) (Effect= 0.22
SD, P= 3.8 × 10−22) (Table 1) that is detected both in Iceland
and UK (MAF in Iceland= 0.48%, and MAF in the UK= 0.12%).
Arg168Trp also associates with increased risk of polycythemia
(OR= 1.56, P= 4.0 × 10−9, hemoglobin levels > 152 g/L for
women and >171 g/L for men) (Table 3, Supplementary Data 7).
We identified seven homozygous carriers of Arg168Trp in the
Icelandic dataset. The genotypic effect on hemoglobin concentra-
tion in homozygous carriers of Arg168Trp is consistent with an
additive model (Supplementary Fig. 9). The variant is located
within domain 1 of ACO1 shown to be important for IRE-RNAs
binding of ACO1, suggesting that the variant might lead to
reduced RNA binding (Fig. 2)25,28. Second, the missense variant
NP_001265281.1:p.Asn549Ile (rs750337798[T]) (Effect= 0.20
SD, P= 6.9 × 10−6) (Table 1) is only found in the Icelandic
population (MAF= 0.21%) (Supplementary Data 5). The variant
is at a highly conserved genomic position (GERP= 6.05, top 0.8%
of the exome and top 0.1% of the genome, Supplementary
Table 8) and the amino acid substitution is located very close to
Arg536, Arg541, and Lys551, which are critical for IRE-RNA
Fig. 1 Pedigree of carriers of Cys506Ser in ACO1. All 62 carriers can be traced back to ancestors born in the late 18th century. The founding couple had
eight offspring and a current total number of 5,430 descendants. Roman numerals indicate generation, mean hemoglobin concentration is noted below the
symbols. square=male, circle= female, diamond= sex unspecified, solid filled object= carrier, half filled object= obligate carrier, red filled object=
persistent anemia.
Fig. 2 Schematic diagram of the ACO1 protein domain structure. Central core domains 1 (yellow) and 2 (green), domain 3 (blue), linker (gray), and
domain 4 (red) (based on Walden et al.25). Red lollipops represent cysteine residues required for iron–sulfur binding and aconitase function. Blue lollipops
represent the amino acids required for binding to the iron-response element found on mRNA transcripts of various proteins required for stable
erythropoiesis. Black arrows represent the sex rare coding variants we report associating with hemoglobin concentration. The axis is the numbers of each
of the total 889 amino acids of ACO1. Protein reference: NP_001265281.1.
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binding of the ACO1 protein24,25 (Fig. 2). Third, a rare missense
variant NP_001265281.1:p.Arg802Cys (rs147876514[T]) associ-
ates with increased hemoglobin concentration (Effect= 0.43 SD,
P= 9.1 × 10−4) (Table 1). This variant is only detected in the UK
(MAF= 0.01%) and is located within domain 4 of ACO1, which
is important for IRE-RNA binding (Fig. 2).
Common variants. Two distinct common noncoding variants
rs12985[C] and rs7045087[C] in ACO1 associate with increased
and decreased hemoglobin levels, respectively, (r2= 0.13)
(Table 1, Supplementary Table 3). The intergenic variant
rs7045087[C] has only one highly correlated variant (rs1133071
[G], r2= 0.81) and was reported by others to associate with a
small effect with reduced hemoglobin levels, RBC and HCT8
(Table 2). The other common variant, the 3′UTR variant rs12985
[C] associates with increased RBC and HCT. rs12985[C] has two
highly correlated variants (r2 > 0.8; rs10813817[C] intronic in
ACO1, rs201050034[G] intronic in DDX58). As expected, rs12985
[C] associates with increased risk of polycythemia (OR= 1.06,
P= 9.0 × 10−9) and decreased risk of anemia (OR= 0.97, P=
4.0 × 10−6) (Table 3). Neither rs12985[C] nor rs7045087[C] show
a strong correlation (r2 > 0.8) with the top cis-eQTL in the region
and rs7029002[C] does not associate with hemoglobin con-
centration (Effect=−0.007 SD, P= 0.076) making it unlikely
that the association of rs12985[C] and rs7045087[C] with
hemoglobin is through an effect on expression.
Previously reported hemoglobin associated variants. We show
association results for 175 reported associations of sequence
variants with hemoglobin concentration, 138 of which have
previously been reported in populations of European descent. The
large majority of reported variants (N= 119) come from the
hitherto largest hemoglobin GWAS reported by Astle et al.8,
where the UK biobank participated with 87k individuals1, which
comprises 22% of the UK biobank dataset used in the current
study (Supplementary Data 2).
Out of the 138 variants reported in European populations, 131
were tested in both the Icelandic and UK datasets and all show a
direction of effect that is consistent with the initial report. In
Iceland, 113 out of the 131 variants replicate (Supplementary
Data 2 and Supplementary Fig. 10). For the combined Icelandic
and UK datasets 129 out of 131 variants replicate. We also
compared effects in standardized and raw scale (g/L) for the 131
hemoglobin associated variants reported in European populations
to explore whether there is a difference in effect estimates
between the Icelandic and UK datasets (Supplementary Data 2
and Supplementary Fig. 10). There are 27% higher effect
estimates on the standardized scale in the UK dataset than in
the Icelandic one (ratio of effect UK/Iceland= 1.27 (95% CI
1.23–1.32)). We note that the variance of raw hemoglobin
concentration is higher in the Icelandic dataset than in the UK
one (SD of raw hemoglobin concentration: Iceland= 15.5 g/L,
UK= 12.2 g/L) (Supplementary Table 1). Once effect estimates
are converted to raw scale (g/L) the effects are almost identical in
the Icelandic and UK datasets (ratio of effect UK/Iceland= 1.02
(95% CI 0.99–1.06)) (Supplementary Fig. 10). Thus, it appears
that the difference in effect estimates on the standardized scale
between UK and Iceland can largely be explained by the higher
variance in hemoglobin concentration in Iceland.
The UK and Iceland datasets included in the present analysis
are diverse in regard to recruitment practices9,29. Despite
differences in age, population coverage, number, and purpose of
measurements between the Icelandic and UK datasets, which are
reflected in differences in the distribution of raw hemoglobin
values (Supplementary Table 1 and Supplementary Fig. 2), we still
observe similar effect of sequence variants on hemoglobin
concentration in the two datasets (Table 1, Supplementary Data 2,
and Supplementary Fig. 10).
Discussion
The aim of this study is to understand how sequence variants in
ACO1 affect hematopoiesis. After we identified a genome-wide
significant association at the ACO1 locus, we performed condi-
tional analysis to search for secondary associations at the locus,
focusing on variants with a predicted protein-coding effect. We
describe two noncoding variants at the ACO1 locus and six dis-
tinct rare coding variants in ACO1 with minor alleles that
associate with either decreased (Cys506Ser and Thr208Ala) or
Fig. 3 Pedigree of carriers of Lys334Ter in ACO1. All 67 carriers can be traced back to a common ancestor in the early 18th century. The founding couple
had six offspring and a current total number of 21,423 descendants. Roman numerals indicate generation, year of birth of the founding couple is noted
above the symbols and mean hemoglobin concentration is noted below the symbols. Square=male, circle= female, diamond= sex unspecified, solid filled
object= carrier, half filled object= obligate carrier, red filled object= polycythemic.
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increased (Lys334Ter, Arg168Trp, Asn549Ile, and Arg802Cys)
hemoglobin concentration. These variants also associate with
RBC and HCT where the direction and magnitude of effect is
consistent with their association with hemoglobin. However,
none of these variants associate with MCV and MCHC, indi-
cating that ACO1 sequence variants affect the production of RBC
but not the hemoglobin content of each cell. Furthermore, the
effects on hemoglobin range from −1.61 to 0.63 SD demon-
strating that they affect the protein function both in the opposite
manner and to a different degree.
The two variants in ACO1 with largest effects are both likely
to have pronounced effects on protein function with the larger
effect of Cys506Ser an order of magnitude larger than that of
any previously reported sequence variants associating with
decreased hemoglobin concentration: carriers have −1.61 SD
less hemoglobin, which corresponds to 24.6 g/L. This leads to a
very high risk of persistent anemia among carriers (OR= 17.1).
Structural studies have shown that when the [4Fe–4S] cluster is
intact, protein domain 4 is folded over and covers the [4Fe–4S]
cluster within the central core formed by domains 1 and 230.
When the iron–sulfur cluster disassembles because of iron
depletion (and/or because of oxidative degradation of the
cluster) or when mutations in any of the [4Fe–4S] binding
cysteines prevent cluster binding, domain 4 moves by a flexible
hinge linker exposing the core domains. This allows the IRE
structure to bind specifically to the protein25,30,31. The Cys506
residue is one of three cysteines directly involved in binding of
the [4Fe–4S] cluster to ACO1. Mutating any of these three
cysteines to serine leads to constitutive activation of the RNA-
binding capacity of ACO1 as the [4Fe–4S] cluster is unable to
bind ACO120,24,32. The effect on serum ferritin levels we
observe is direct evidence that the Cys506Ser is acting as a
constitutively active variant. Constitutive RNA-binding activity
presumably leads to anemia through binding of ACO1 to the
IRE elements of one or more of IRE containing transcripts,
involved in erythropoiesis, and affecting their translation. Two
known IRE containing genes have direct links to erythropoiesis,
EPAS1 (encoding HIF2α) and ALAS2, both carrying 5′UTR IRE
elements33.
The variant with the second largest effect on hemoglobin is the
stop-gained variant Lys334Ter that associates with increased
hemoglobin concentration and increased risk of polycythemia.
The variant is within domain 2 of the protein and is thus pre-
dicted to truncate the protein at amino acid 334 out of the 889
amino acid of the full-length protein. The truncated protein lacks
fraction of domain 2 together with domains 3 and 4 and thus
predicted to have lost its RNA-binding capacity30. Furthermore,
sequencing of RNA from the blood of heterozygous carriers of
Lys334Ter showed a 17% reduction in total RNA compared with
noncarriers. Although, disruption of ACO1 has not been linked
to Mendelian condition in humans, our data are consistent with
Aco1 homozygous knockout mice that show symptoms of poly-
cythemia and pulmonary hypertension, suggested to be caused by
translational derepression of HIF2α (EPAS1) and subsequent
elevation of serum EPO levels from the kidney and endothelin-1
levels from pulmonary endothelial cells21,22. There are no reports
of pulmonary hypertension in carriers of Lys334Ter although it
should be emphasized that we found no homozygous carriers. We
speculate that the coding variants associated with increased
hemoglobin concentration likely reduce the IRE-binding activity
of ACO1, though it is not clear how that would happen based on
co-crystal structures. None of the four coding variants identified
are in close proximity to the amino acids known to most
adversely affect IRE binding: Arg269, Lys379, Ser371, and Ser681.
However, Asn549Ile is close to Lys551, which binds A15 of
the IRE.
Both variants Cys506Ser and Lys334Ter are pedigree-specific
and are of independent origin. We traced both back to common
ancestors born in the 18th century, eight and ten generations ago.
It is of note that identification of the pedigrees was not based on a
priori knowledge of membership but rather enabled by sampling
a large fraction of the population. A few factors are necessary for
the detection of associations with such recent variants. First, the
whole-genome sequencing of a large fraction of the Icelandic
population (~9%) allows the detection of these rare variants.
Second, the large fraction of chip-typed Icelanders (~50% or
155k) enables imputation of these variants into a reasonable
number of carriers. Third, hemoglobin concentration is available
for vast majority (93%) of chip-typed Icelanders and a large
fraction of their relatives.
Finding several variants in the same gene that affect the
function of the protein it encodes can lead to a better under-
standing of the role of the protein in both normal and abnormal
biology. Here we report sequence variants with both loss- or gain-
of-function that affect the same gene. Loss-of-function variants
allow the identification of processes for which a gene is required,
while gain-of-function variants in the same gene indicate that the
gene is able to control the process it affects in a rheostatic
manner34. The effects the ACO1 variants have on hemoglobin
and ferritin, either increasing or decreasing levels, suggest a
regulatory function of ACO1 with effects that go both ways. The
effects of the loss-of-function variants reported here most likely
result from ACO1 haploinsufficiency, as we demonstrate for the
stop-gained heterozygotes for Lys334Ter. The underlying
mechanism of gain-of-function variants are usually harder to
explain34. In case the of the Cys506Ser variant, the mechanism is
well studied in model systems and is the result of a gain of IRE
binding. Other coding variants in ACO1 that produce similar
phenotypic effects are most likely to go through the same
mechanism of action. Both loss- and gain-of-function variants in
PCSK9 have been identified that decrease and increase cholesterol
levels, respectively, and led to the development of PCSK9 inhi-
bitors to reduce LDL cholesterol levels35. Also, loss- and gain-of-
function variants in SCN9A encoding a voltage-gated sodium
channel cause syndromes encompassing decrease and increase in
pain perception, respectively, and have triggered efforts to
develop SCN9A inhibitors as a therapeutic36. The identification
of loss- and gain-of-function variants in ACO1 sheds light on
mechanisms that could be exploited in the development of
therapies targeting erythropoiesis. We provide evidence for
ACO1 as a potential drug target for treatment of disorders of
erythropoiesis.
Methods
Study subjects. The meta-analysis combined the results of two GWAS of
hemoglobin concentration. The Icelandic dataset consisted of hemoglobin con-
centration measurements from 1993 to 2016 of 286,622 Icelanders available from
four different laboratories in Iceland. In the UK Biobank, hemoglobin concentra-
tions from 397,500 participants were measured from 2007 to 2010.
All participating Icelandic individuals who donated blood, or their guardians,
provided written informed consent. The family history of participants donating
blood was incorporated into the study by including the phenotypes of first- and
second-degree relatives and integrating over their possible genotypes.
All sample identifiers were encrypted in accordance with the regulations of the
Icelandic Data Protection Authority. Approval for the study was provided by the
Icelandic National Bioethics Committee (ref: VSNb2015010033-03.12).
Genotyping. The Icelandic part of the study is based on testing variants identified
by whole-genome sequence (WGS) data from 28,075 Icelanders participating in
various disease projects at deCODE genetics, sequenced using Illumina standard
TruSeq methodology to an average genome-wide coverage of 37×. The effects of
sequence variants on protein-coding genes were annotated using the variant effect
predictor using protein-coding transcripts from RefSeq. We carried out chip typing
of 155,250 Icelanders (around 50% of the population) using Illumina SNP arrays as
previously described9,37. The chip-typed individuals were long-range phased38, and
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0921-5 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:189 | https://doi.org/10.1038/s42003-020-0921-5 | www.nature.com/commsbio 7
the variants identified in the whole-genome sequencing of Icelanders were imputed
into the chip-typed individuals (Imputation info > 0.8 and MAF > 0.01%). In
addition, genotype probabilities for 285,644 untyped close relatives of chip-typed
individuals were calculated based on Icelandic genealogy. The whole-genome
sequenced samples were variants called jointly and the sequence variants found
through whole-genome sequencing were phased jointly. The process used for WGS
sequencing of Icelanders, and the subsequent imputation from which the data for
this analysis were generated has been extensively described in recent
publications9,37.
Genotyping of UK biobank samples was performed using a custom-made
Affymetrix chip, UK BiLEVE Axiom39, and with the Affymetrix UK Biobank
Axiom array40. Imputation was performed by Wellcome Trust Centre for Human
Genetics using variants identified from 32,488 WGS individuals in the HRC and
the UK10K haplotype resources17. This yields a total of 96 million imputed
variants, however only 40 million variants were imputed into 408,658 participants
using the HRC reference set due to quality issues with the remaining variants.
Determination of sequence variant origin. Close to complete genealogical
records of the Icelandic population are available dating back to the Icelandic
national census of 1703, and incomplete records dating back to the settlement of
Iceland in 874 CE41,42. The Icelandic genealogy coupled with the large fraction of
the population that has been chip-typed allows us to determine the origin of
sequence variants through long-range phasing and haplotype imputation9. We
used the Icelandic genealogy database42,43 to identify the most recent common
ancestors of carriers of the two rarest ACO1 sequence variants, Cys506Ser and
Lys334Ter. In both cases, all carriers shared a common ancestor. These sequence
variants are absent from descendants of close relatives of the common ancestor
carrying the same haplotype background.
Phenotypes. Hemoglobin measurements: In the Icelandic part of the study, we
used 4,354,272 hemoglobin concentration measurements from 286,622 Icelanders
from four different laboratories in Iceland from 1993 to 2018 (Supplementary
Tables 1, 4, and 5). Of the 286,622 individuals with hemoglobin measured, 143,682
were chip-typed and 142,940 were first- or second-degree relatives of chip-typed.
The geometric mean for number of measurements per subject is 6.4. In the
laboratories, hemoglobin concentration was measured using routine automated
and semiautomated hematology analyzers. Hemoglobin concentration measure-
ments for each sex and the four different laboratories were separately transformed
to a standard normal distribution and adjusted for age using a generalized additive
model17,44.
From the UK Biobank we used 418,628 hemoglobin concentration
measurements from 397,500 individuals of white British ancestry, whose samples
were collected at the UK Biobank assessment centers (Field ID 30020, hemoglobin
concentration) (Supplementary Table 10). The median for number of
measurements per subject is one measurement. The samples were processed and
analyzed at the centralized processing laboratory of UK Biocenter using clinical
hematology analyzers. The hemoglobin concentration measurements were adjusted
for age and sex and population stratification using 40 principal components.
Hemoglobin concentration measurements as well as other basic hematology
parameters used in the expression correlation were measured on EDTA
anticoagulated blood using the Sysmex XN-1000 hematology analyzer.
Anemia: When deriving anemia status from the hemoglobin concentration
measurements, an individual was defined to be anemic if all of their measured
hemoglobin concentrations were below the anemic diagnostic threshold (below
118 g/L for women and below 134 g/L for men).
Heritability: Heritability of hemoglobin concentration was estimated in the
following two ways: (1) 2 × parent–offspring correlation, (2) 2 × full sibling
correlation, using the Icelandic data (where all family relationships are known).
Association analysis. We performed a meta-analysis on 286,622 individuals
from Iceland and 397,500 individuals from the UK Biobank with at least one
hemoglobin concentration measurement. In Iceland, quantitative traits were
tested using a linear mixed model implemented in BOLT-LMM45. We tested
37,592,353 variants (with imputation info > 0.8 and MAF > 0.01%) identified
from the whole-genome sequencing of 28,075 Icelanders (~9% of the popula-
tion) for association with hemoglobin concentration. For binary phenotypes, sex,
county of birth, current age or age at death (first- and second-order terms
included), blood sample availability for the individual, and an indicator function
for the overlap of the lifetime of the individual with the time span of phenotype
collection were included as covariates in the logistic regression model. In the UK
Biobank study, 40 principal components were used to adjust for population
stratification and age and sex were included as covariates in the logistic
regression model and the BOLT-LMM. The quantitative traits were transformed
to a standard normal distribution. Only white British individuals were included
in the study.
For the meta-analysis we used a fixed-effects inverse variance method based on
effect estimates and standard errors from the Icelandic and the UK Biobank
study46. For each study we used linkage disequilibrium (LD) score regression to
account for distribution inflation in the dataset due to cryptic relatedness and
population stratification47. Using a set of about 1.1 million sequence variants with
available LD score, we regressed the χ2 statistics from our GWAS scan against LD
score and used the intercept as correction factor. The estimated correction factor
for hemoglobin concentration based on LD score regression was 0.68 for the
additive model in the Icelandic sample and 1.40 in the UK Biobank. In Iceland,
when testing the association of sequence variants with quantitative traits, a BOLT
linear mixed model was applied. These models are now widely used as they account
for cryptic relatedness while also increasing power45. One-step in the BOLT-LMM
procedure (step 1b) is to calibrate the χ2 test statistic by calculating a constant
calibration factor. To compute the calibration constant BOLT-LMM rapidly
computes the prospective statistic at 30 random SNPs by applying conjugate
gradient iteration. However, this scaling was not applied to the test statistic in the
Icelandic association model. Therefore, when we applied the LD score regression
and estimate a correction factor from the regressions intercept it was shifted by this
constant factor. The correction factor can thus indeed be below one due to the
calibration factor (Supplementary Fig. 11). The intercept is therefore not
comparable with correction factors obtained from standard genomic control
methods, and should not be interpreted as such. Expected allele counts for
sequence variants were used as covariates in the regression to test for association
with other sequence variants conditional on their effects.
Significance thresholds. We applied genome-wide significance thresholds cor-
rected for multiple testing using a weighted Bonferroni correction that controls the
family-wise error rate. Based on variant annotation classes the weights used are the
predicted functional impact of the class18. A total of 45,078,764 sequence variants
were tested in either deCODE or the UK Biobank data. The adjusted significance
thresholds are 1.8 × 10−7 for variants with high impact (N= 12,456), 3.5 × 10−8 for
variants with moderate impact (N= 235,454), 3.2 × 10−9 for low-impact variants
(N= 3,334,594), 1.6 × 10−9 for other variants in Dnase I hypersensitivity sites
(N= 5,928,505), and 5.3 × 10−10 for all other variants (N= 35,567,755).
Given that we observe genome-wide significant associations to hemoglobin levels
corresponding to coding variants in ACO1, we decided to test all ACO1 coding
variants with hemoglobin levels. In total, we tested 34 coding variants in ACO1 and
apply a Bonferroni correction significance threshold of 0.05/34= 1.5 × 10−3.
Sanger sequencing and re-imputation. Sequence variant T>A at chr9:32,429,450
(hg38), corresponding to p.Cys506Ser, was poorly imputed due to the low fre-
quency of the variant and low number of sequenced carriers in the original Ice-
landic dataset. A group of probable carriers of p.Cys506Ser and noncarriers were
Sanger sequenced, and re-imputation was subsequently carried out in the same
population. Sanger sequencing confirmed 58 carriers of Cys506Ser and 62 were
identified after re-imputation. Imputation information following re-imputation
increased from 0.94 to 0.97.
RNA-sequencing analysis. RNA sequencing data from whole blood of 13,174
individuals from Icelandic samples. Gene expression was computed based on
personalized transcript abundances48. Association between variant and gene
expression was estimated using a generalized linear regression assuming, additive
genetic effect and normal quantile-transformed gene expression estimates,
adjusting for measurements of sequencing artefacts, demography variables, blood
composition, and hidden covariates49. All variants within 5 Mb of each gene were
tested.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence variants passing GATK filters have been deposited in the European Variation
Archive, accession number PRJEB15197. RNA-seq data have been deposited in the Gene
Expression Omnibus, accession number GSE102870. The genome-wide association scan
summary data will be made available at http://www.decode.com/summarydata.
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